Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

EMBL scientists found start-up company to develop anti-cancer drugs

09.08.2006
Elara Pharmaceuticals GmbH provides a fast track from bench to clinical application

Today EMBL scientists, EMBL’s commercial affiliate, EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) and EMBL’s venture vehicle, EMBL Ventures GmbH, announce the foundation of Elara Pharmaceuticals GmbH, a start-up company that will translate basic research findings into new anti-cancer drugs. Elara is a spin-out company dedicated to drug development and will follow-up on promising small molecule leads that have shown powerful anti-cancer actions in screening experiments. Elara receives seed funding from EMBL Ventures and has been granted exclusive license rights to selected discoveries made at EMBL.

“Elara draws on the skills and know-how of some of Europe’s leading molecular biologists and the cutting-edge technology of EMBL’s Chemical Biology Core Facility”, says George Reid, researcher at EMBL and CEO of Elara. “The EMBL core facility, led by Joe Lewis, who is also a co-founder of ELARA, has tested thousands of small molecules in screens developed during our basic research activities, and identified several series with anti-cancer action. Elara will now take the most promising of these compounds, further develop them and then evaluate their activity in animal models of various types of tumours, such as lung and breast cancer. Through creating a direct flow of information from basic research, preclinical development and application studies, we will greatly speed up the process of drug development.”

Elara will follow-up on promising leads of molecules that block the signaling protein Aurora Kinase A, which is strongly over-expressed in cancer cells, and on inhibitors that affect estrogen receptor signaling, a process essential in the development of breast cancer. EMBO Executive Director, EMBL Senior Scientist and Elara co-founder Frank Gannon heads the world-leading research group studying these receptors. Five lead series of bio-active molecules with different modes of action and diverse chemical structures have already been identified from the two cancer-related signaling pathways.

“Traditionally, there is a significant gap between basic research and drug development”, says Christof Antz, Managing Director of EMBL Ventures. “It often takes years to get from promising findings to a therapeutic approach. With Elara we aim to bridge this gap and create a direct pipeline from the Laboratory by way of animal testing to clinical development.”

Anna-Lynn Wegener | alfa
Further information:
http://www.embl.de
http://www.embl.org/aboutus/news/press/2006/09aug06/index.html

More articles from Health and Medicine:

nachricht New antibody analysis accelerates rational vaccine design
09.08.2018 | Scripps Research Institute

nachricht Distrust of power influences choice of medical procedures
01.08.2018 | Johannes Gutenberg-Universität Mainz

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

Im Focus: The “TRiC” to folding actin

Proteins must be folded correctly to fulfill their molecular functions in cells. Molecular assistants called chaperones help proteins exploit their inbuilt folding potential and reach the correct three-dimensional structure. Researchers at the Max Planck Institute of Biochemistry (MPIB) have demonstrated that actin, the most abundant protein in higher developed cells, does not have the inbuilt potential to fold and instead requires special assistance to fold into its active state. The chaperone TRiC uses a previously undescribed mechanism to perform actin folding. The study was recently published in the journal Cell.

Actin is the most abundant protein in highly developed cells and has diverse functions in processes like cell stabilization, cell division and muscle...

Im Focus: Lining up surprising behaviors of superconductor with one of the world's strongest magnets

Scientists have discovered that the electrical resistance of a copper-oxide compound depends on the magnetic field in a very unusual way -- a finding that could help direct the search for materials that can perfectly conduct electricity at room temperatur

What happens when really powerful magnets--capable of producing magnetic fields nearly two million times stronger than Earth's--are applied to materials that...

Im Focus: World record: Fastest 3-D tomographic images at BESSY II

The quality of materials often depends on the manufacturing process. In casting and welding, for example, the rate at which melts solidify and the resulting microstructure of the alloy is important. With metallic foams as well, it depends on exactly how the foaming process takes place. To understand these processes fully requires fast sensing capability. The fastest 3D tomographic images to date have now been achieved at the BESSY II X-ray source operated by the Helmholtz-Zentrum Berlin.

Dr. Francisco Garcia-Moreno and his team have designed a turntable that rotates ultra-stably about its axis at a constant rotational speed. This really depends...

Im Focus: A molecular switch may serve as new target point for cancer and diabetes therapies

If certain signaling cascades are misregulated, diseases like cancer, obesity and diabetes may occur. A mechanism recently discovered by scientists at the Leibniz- Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin and at the University of Geneva has a crucial influence on such signaling cascades and may be an important key for the future development of therapies against these diseases. The results of the study have just been published in the prestigious scientific journal 'Molecular Cell'.

Cell growth and cell differentiation as well as the release and efficacy of hormones such as insulin depend on the presence of lipids. Lipids are small...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

2018 Work Research Conference

25.07.2018 | Event News

 
Latest News

Breaking down the Wiedemann-Franz law

13.08.2018 | Physics and Astronomy

Joining forces for immune research

13.08.2018 | Life Sciences

Another step forward on universal quantum computer

13.08.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>